WESTPORT, Conn., April 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it is expanding its evaluation of strategic alternatives and implementing additional measures to extend its available cash runway. After a review of the Company’s future funding needs for... Read More

WESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it has completed selling its equity holding in Intensity Therapeutics (NASDAQ: INTS). Portage was an early INTS investor and during the past few months, Portage has been able to monetize its... Read More

WESTPORT, Conn., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended December 31, 2023. “The Company is focused on advancing its ADPORT-201 Phase 1a/1b clinical trial of PORT-6 (adenosine 2A... Read More

Prioritize the adenosine clinical candidates iNKT clinical development paused to focus resources Company will evaluate range of strategic options WESTPORT, Conn., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today announced the outcome from the company’s comprehensive review... Read More

WESTPORT, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended September 30, 2023. “The Company is focused on developing its two lead clinical programs and maximizing its resources given market conditions. We... Read More

Updated data support the proof of concept of using an iNKT engager monotherapy (PORT-2) to induce immune response for patients with non-small cell lung cancer (NSCLC) and melanoma Strong academic interest in the design of the Adenosine 2A(A2A) and Adenosine 2B(A2B) trial for patients with solid tumors with high adenosine receptor expression WESTPORT, Conn., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc . (NASDAQ:... Read More

WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of an aggregate of 3,157,895 shares of its common stock (or common stock equivalents in... Read More

WESTPORT, Conn., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will participate in a panel discussion at the Cantor Global Healthcare Conference on Thursday, September 28, 2023 at 10:20 – 10:50 AM ET in New York, NY. The... Read More

WESTPORT, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today announced that it has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the US and Canada) to evaluate Portage’s next-generation adenosine antagonists in combination with... Read More

WESTPORT, Conn., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended June 30, 2023. “In recent weeks we have continued to build on the favorable interim data and early evidence of single agent activity from the Phase 1/2... Read More

Company poised to accelerate accrual in all clinical programs as it activates numerous sites across multiple U.S. cities and abroad and takes over sponsorship from the investigator-led program Updated interim data for lead iNKT engager, PORT-2, presented at the 2023 ASCO Annual Meeting showed early evidence of monotherapy activity with minimal toxicity First patient dosed in Phase 1a trial of PORT-6 (A2AR antagonist) in... Read More

WESTPORT, Conn., June 26, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, announced today that it has dosed the first patient in its Phase 1a trial, ADPORT-601 ( NCT04969315 ). The trial is evaluating Portage’s adenosine 2A receptor (A2AR) antagonist candidate, PORT-6, in patients with... Read More

Interim data presented at ASCO show early evidence of single agent activity with meaningful reduction of several target lesions Based on the favorable safety and tolerability data at all doses tested to date, the Company intends to expand Phase 1 portion of the trial to evaluate higher dose levels; with data anticipated by end of 2023 WESTPORT, Conn., June 05, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a... Read More

WESTPORT, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, announced today that CEO Dr. Ian Walters will serve as an expert spokesperson on an oncology panel discussion at the upcoming BIO International Conference taking place in Boston, Massachusetts June 5-8, 2023.... Read More

WESTPORT, Conn., April 26, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, announced the acceptance of a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago, IL. The poster will include updated data from the... Read More

WESTPORT, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will be presenting virtually at Oppenheimer’s 33 rd Annual Healthcare Conference on March 13-15, 2023. Presentation details are below: Oppenheimer 33 rd Annual... Read More

Enrollment ongoing in IMPORT-201 Phase 1/2 trial of PORT-2 in Melanoma and Non-Small Cell Lung Cancer Company on track to initiate Phase 1 portion of ADPORT-601 trial by end of 2Q23 Company to Host a Key Opinion Leader Event on Targeting Adenosine Pathway in Cancer WESTPORT, Conn., March 01, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted... Read More

Targeting Adenosine for Cancer: Challenging Past Assumptions with Next-Generation Small Molecule Inhibitors Thursday, March 9 th @ 10:30 am ET WESTPORT, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that it will host a key opinion leader (KOL) webinar... Read More

WESTPORT, Conn., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will participate in a fireside chat at Citi's 2023 Virtual Oncology Leadership Summit taking place on Febrarury 21 – 23, 2023. Event details are below: Citi's... Read More

The Company Highlights its Clinical Strategy for its Adenosine and iNKT Platforms Clinical Development Goals are Focused on Producing Phase 1b/Phase 2 Efficacy Readouts in Multiple Tumor Types Over the Next two Years Portage Biotech Inc . (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today provided an update on its research and development... Read More

Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced that the Company’s management team will be presenting at the following upcoming investor conferences: H.C. Wainwright 24 th Annual Global Investment Conference Date / Time: September 13, 2022 at 9:30am ET Format: Company Presentation Cantor Fitzgerald’s Oncology,... Read More

Robust Pipeline Now Includes Five Clinical-Stage Small Molecule Immuno-Oncology Assets, Including Invariant Natural Killer T Cell (iNKT) Agonists and Adenosine Antagonists Cash Runway for New and Current Programs Potentially Extended into 2024 Portage Biotech Inc . (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced financial results... Read More

CEO Dr. Ian Walters to take on additional responsibility as Chairman of the Board Justin Fairchild, MPH, an expert in clinical immunotherapy, appointed Vice President of Development Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced that Dr. Ian Walters, Chief Executive Officer of Portage, will be appointed... Read More

Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions Robust Pipeline Now Includes Four Fully Owned, Clinical-Stage Assets Cash Runway for New and Current Programs Potentially Extended into 2024 Portage Biotech Inc . (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and... Read More

Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that the Company has acquired the outstanding ownership interest (approximately 22%) of its invariant natural killer T cell (iNKT agonist) platform and now fully owns the worldwide rights to its small molecule... Read More

Acquires two clinical-stage, best in class adenosine compounds, and two preclinical assets for approximately $21 million upfront consideration Rob Glassman, M.D., Ph.D., director of Tarus and former Venture partner at OrbiMed, to join the Portage Board of Directors Enters into committed share purchase agreement with Lincoln Park Capital to purchase ordinary shares of Portage for up to $30 Million; proceeds to potentially... Read More

Portage Biotech Inc . (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that the Company presented early data from its Phase 1/2 study of PORT-2 (IMM60), an invariant natural killer T cell (iNKT) agonist for patients with melanoma and non-small cell lung cancer (NSCLC), at the... Read More

Collaboration will advance preclinical and potential clinical development of STING agonists and anti-RAGE agents for cancer vaccines Portage and NCI will develop agents to enhance the efficacy of proprietary cancer vaccines and mouse model cancer vaccines developed by the NCI Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by... Read More

Portage Biotech Inc. , (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today highlighted data being presented in collaboration with Stimunity during the American Association for Cancer Research (AACR) 2022 Annual Meeting taking place April 8-13 in New Orleans,... Read More

Preliminary safety data suggests lead iNKT agonists, PORT-2 and PORT-3, are well tolerated supporting continued development Company continues to work toward multiple clinical readouts in 2022 Portage is accelerating studies by expanding regions and clinical sites; continued advancement of pipeline beyond iNKTs Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company... Read More

Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, and Stimunity, an early-stage biotech company focused on the development of a unique STING agonist based on virus-like particles, today announced data from a collaboration on a STING-activating... Read More

Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results for the quarter ended December 31, 2021 (the “third quarter”). “During the third quarter and in recent weeks we’ve taken steps to accelerate our lead programs for... Read More

Leading biopharma executive Brian Wiley joins as Chief Business Officer Experienced financial consultant Joseph Ciaverella advances to new role as Chief Accounting Officer Jim Mellon, Linda Kozick and Mark Simon will join Portage’s Board of Directors Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by... Read More

Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that the Company will participate in three investor conferences during the month of January. As part of the Company’s participation, CEO Dr. Ian Walters will join other thought... Read More

Initiated PORT-2 Phase 1/2 IMP-MEL trial in patients with Melanoma & NSCLC Enrollment ongoing in Phase 1 PRECIOUS-01 study of PORT-3 for the treatment of NY-ESO-1 positive solid tumors Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today... Read More

Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that Chief Executive Officer, Dr. Ian Walters, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29-December 2, 2021. Dr.... Read More

Data presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and Connective Tissue Oncology Society (CTOS) Annual Meeting suggest INT230-6 (PORT-1) offers a promising approach to treating metastatic disease, including advanced soft tissue sarcomas Data from Intensity Therapeutics’ Phase 2 IT-01 clinical trial show that INT230-6 (PORT-1) is safe when administered both as a monotherapy and in... Read More

Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that it will host a key opinion leader (KOL) webinar on the role iNKT cells play in anticancer immune response and how iNKT targeting can be leveraged to expand the immuno-oncology... Read More

Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that as part of its commitment to investor outreach, management will be participating in the following investor conferences in September 2021. H.C. Wainwright 23rd Annual Global Investor Conference Date:... Read More

$29 million raised during quarter with broad institutional support Proceeds will accelerate advancement of clinical pipeline toward multiple data readouts over the next 18-24 months Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced financial results for the... Read More

Portage Biotech Inc ., (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today issued the following letter to shareholders: Dear Shareholders, On behalf of the team at Portage Biotech, Inc., I am pleased to provide you with a corporate update, reflecting on the progress that we have made throughout the first half... Read More

Novel iNKT agonist leads to a broad reprogramming of the innate and adaptive immune system to target cancer PORT-2 has the potential to re-sensitize checkpoint-resistant tumors to treatment with PD-1 antibodies Portage Biotech Inc. , (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that the first... Read More

Transformative year included multiple corporate, clinical, and financial milestones, positioning Portage to accelerate development of first-in-class immuno-oncology assets Additional clinical milestones and company progress anticipated throughout 2H 2021 and 2022 Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies and treatments... Read More

Portage Biotech Inc. , (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that the Company has been added to the Russell 2000  Index at the conclusion of the 2021 Russell Indexes annual reconstitution, effective after the U.S. market opened on June 28. "Inclusion in the Russell 2000 index marks... Read More

Portage Biotech Inc. (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that it has priced its previously announced underwritten public offering of 1,000,000 ordinary shares. The public offering price of each ordinary share is $23.00. In addition, Portage has granted the underwriters... Read More

Portage Biotech Inc. (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that it has commenced an underwritten public offering of its ordinary shares. In addition, Portage expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of the... Read More

Portage Biotech Inc. , (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today highlighted that Intensity Therapeutics will present interim data from the Phase 2 portion of its IT-01 trial evaluating the safety and efficacy of INT230-6 (PORT-1) as both a monotherapy and in combination with pembrolizumab or... Read More

Portage Biotech Inc. , (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that it plans to voluntarily delist its common shares ("Shares") from the Canadian Securities Exchange (the "CSE"). Since Portage's Shares began trading on the NASDAQ Capital Market ("Nasdaq") in February 2021,... Read More

Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company"), a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that the first patient has been dosed in the Phase 1 portion of the PRECIOUS-01 open-label, dose-escalation and expansion clinical trial assessing the safety, tolerability, efficacy and dosing of... Read More

Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical stage immuno-oncology company accelerating research and development to overcome immune resistance, today highlights that Intensity Therapeutics has executed agreements to conduct a Phase 2 study of INT230-6 (PORT-1) in early stage breast cancer in tandem with the Ottawa Hospital Cancer Centre and The Ontario Institute for Cancer... Read More

Out-licensing agreement facilitates focus on the Company's immuno-oncology assets Portage may be entitled to up to USD $244 million in future milestone payments Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical stage immuno-oncology company accelerating research and development to overcome immune resistance, today announced the divestment of its three legacy businesses; Portage... Read More